Moreover, multiple studies have linked NF1 activity to RAS and ERK activity [28, 29, 33–36], including its role in therapy resistance upon targeted inhibition of the MAPK pathway in melanoma [28, 29, 36, 37] and lung cancer [38]. This evidence concerns the gene NF1 and lung carcinoma.